Creating a protein to detoxify harmful substances in the blood.
Bioengineering a Dual Function Protein Construct to Detoxify Heme and Hemoglobin
['FUNDING_R01'] · OHIO STATE UNIVERSITY · NIH-10857279
This study is looking at a new treatment that could help people with hemolytic diseases by creating a special protein that can safely remove harmful substances from the blood, which can help prevent serious health problems like high blood pressure and organ damage.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | OHIO STATE UNIVERSITY (nih funded) |
| Locations | 1 site (Columbus, UNITED STATES) |
| Trial ID | NIH-10857279 on ClinicalTrials.gov |
What this research studies
This research focuses on developing a new protein construct that can effectively detoxify free heme and hemoglobin released into the bloodstream during hemolytic conditions, which can lead to serious health issues like hypertension and organ damage. The approach involves engineering a complex of apohemoglobin and haptoglobin that can bind to these harmful substances, thereby reducing their adverse effects. By enhancing the stability and functionality of this protein complex, the research aims to provide a novel treatment option for patients suffering from hemolytic diseases.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with acquired or genetic hemolytic diseases.
Not a fit: Patients without hemolytic conditions or those not experiencing adverse effects from free heme and hemoglobin may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved treatments for patients with hemolytic diseases, reducing complications and enhancing overall health outcomes.
How similar studies have performed: Previous studies have shown promise in using similar protein constructs for detoxification, indicating potential for success in this novel approach.
Where this research is happening
Columbus, UNITED STATES
- OHIO STATE UNIVERSITY — Columbus, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: PALMER, ANDRE FRANCIS — OHIO STATE UNIVERSITY
- Study coordinator: PALMER, ANDRE FRANCIS
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.